Autoimmune liver disease panel

An autoimmune liver disease panel is a group of blood tests for antibodies that may appear when the immune system mistakenly reacts against the liver or bile ducts.

There is no standard panel used by every laboratory. It may include:

• Antinuclear antibodies, or ANA
• Smooth muscle antibodies, or SMA
• Liver-kidney microsomal type 1 antibodies, or anti-LKM1
• Soluble liver antigen antibodies, or anti-SLA
• Antimitochondrial antibodies, or AMA
• PBC-specific antibodies such as anti-gp210 or anti-sp100
• Immunoglobulins, especially IgG and sometimes IgM

Results are interpreted with liver blood tests, symptoms, medical history, imaging and sometimes a liver biopsy. A positive result alone does not confirm autoimmune liver disease.

The panel is mainly used to investigate unexplained abnormal liver blood tests. Different patterns may support different diagnoses:

• ANA, SMA, anti-LKM1 and anti-SLA may support autoimmune hepatitis
• AMA and PBC-specific antibodies may support primary biliary cholangitis, or PBC
• Immunoglobulin levels may provide additional evidence

Autoimmune hepatitis causes inflammation in liver tissue. PBC mainly damages the small bile ducts within the liver.

Primary sclerosing cholangitis, or PSC, affects larger bile ducts but has no reliable diagnostic autoantibody. Bile duct imaging is usually more useful when PSC is suspected.

Testing may also form part of an assessment for persistent itching, fatigue, yellow skin or eyes, or discomfort under the right ribs. These symptoms have many possible causes.

A healthcare professional may suggest the panel if you have unexplained changes in liver enzymes, bilirubin or alkaline phosphatase, particularly when initial tests have not identified a cause.

Testing may be more relevant if you have another autoimmune condition or a relevant family history. It is not generally used to screen people without symptoms, risk factors or abnormal liver results.

The tests should match the clinical question. AMA may be useful when results suggest impaired bile flow, while ANA, SMA and IgG may be chosen when autoimmune hepatitis is suspected.

You usually do not need to fast. Food, water and coffee do not normally affect autoantibody results.

If other blood tests are being collected, follow their preparation instructions because some may require fasting.

Tell the healthcare professional about your medicines and supplements. Do not stop prescribed treatment unless specifically instructed. Medicines that suppress the immune system may lower antibody or immunoglobulin levels and affect interpretation.

Also mention pregnancy, recent infections, autoimmune conditions, immunoglobulin treatment and any previous liver diagnosis.

A healthcare professional places a band around your upper arm, cleans the skin and inserts a needle into a vein, usually near the elbow. One or more tubes of blood are collected.

The blood draw usually takes less than 10 minutes. You can normally leave immediately and resume your usual activities.

Some specialist antibodies are tested at another laboratory, which may delay results.

Results may be negative, positive, weakly positive, numerical or reported as a titre. A titre indicates how much the sample can be diluted before the antibody is no longer detected.

There is no universal normal range for the whole panel. Laboratory methods and cut-offs differ, and results must be interpreted in context.

Common patterns include:

• Negative antibodies: Make some autoimmune liver diseases less likely but do not exclude them
• Positive ANA or SMA: May support autoimmune hepatitis, especially with raised IgG and compatible liver findings, but can occur in other conditions
• Positive anti-LKM1 or anti-SLA: Can provide stronger support for certain forms of autoimmune hepatitis
• Positive AMA: Can strongly support PBC when liver tests also show impaired bile flow
• Raised IgG: May support autoimmune hepatitis but is not specific
• Raised IgM: Can occur with PBC but does not establish the diagnosis

A higher antibody result does not automatically mean greater liver damage. Liver enzymes, bilirubin, IgG and clinical findings are generally more useful for monitoring disease activity.

Low-level ANA or SMA can occur in healthy people and in people with infections, other autoimmune diseases or non-autoimmune liver conditions.

Corticosteroids like prednisone or hydrocortisone, biologic medicines and other immune-suppressing treatments may lower antibody or immunoglobulin levels. Testing after treatment starts can therefore be less informative.

Intravenous immunoglobulin, or IVIG, can temporarily produce unexpected positive results. Plasma exchange may lower antibody levels or produce a negative result.

Age, sex and pregnancy can affect interpretation. Strenuous exercise does not usually change the antibodies, but it can raise AST and ALT because these enzymes are also found in muscle.

Mention any recent blood transfusion, IVIG or plasma exchange. Results from different laboratories may not be directly comparable because testing methods vary.

No single test detects every case. Some people with autoimmune hepatitis have none of the commonly measured antibodies, particularly after immune-suppressing treatment. A negative panel can therefore miss disease.

False-positive results also occur. ANA and SMA are not liver-specific, while AMA still needs to be interpreted with liver tests and the wider clinical picture.

The panel cannot measure liver scarring or reliably distinguish every overlap syndrome. Other investigations may include ultrasound for gallstones or blocked ducts, magnetic resonance cholangiopancreatography for suspected PSC, viral and metabolic tests, medicine review, or a liver biopsy when the diagnosis or degree of inflammation remains uncertain.

The risks are those of an ordinary blood draw. You may have brief discomfort, a small bruise or feel faint. Infection or ongoing bleeding is uncommon.

If the panel is negative and other liver tests are reassuring, routine follow-up or no further testing may be appropriate. Persistently abnormal liver results may still need investigation because a negative panel does not exclude every cause.

Positive results are reviewed with liver enzymes, bilirubin, immunoglobulins, symptoms and medical history. Follow-up may include repeat blood tests, specialist antibodies, ultrasound, referral to a liver specialist or a liver biopsy.

Contact a healthcare professional promptly if you develop new yellowing of the skin or eyes, very dark urine, increasing abdominal swelling or persistent vomiting.

Seek emergency care for confusion, difficulty staying awake, vomiting blood, black tar-like stools, collapse or severe, rapidly worsening abdominal pain. These symptoms need urgent assessment regardless of the antibody result.

Can I drink coffee before the test?

Yes. Coffee does not usually affect autoimmune liver antibodies. Check whether other tests ordered at the same time require fasting.

Does the time of day matter?

Usually not. These antibodies do not normally vary enough during the day to require morning testing.

Can I exercise beforehand?

Exercise is unlikely to affect the antibodies. However, strenuous exercise can temporarily raise AST and ALT, so mention recent intense activity if liver enzymes are also being checked.

Should I stop my medicines?

No, unless specifically instructed. Immune-suppressing medicines can affect results, but stopping them without guidance may be unsafe.

Does a positive ANA mean I have autoimmune hepatitis?

No. ANA can occur in healthy people and in other conditions. Its meaning depends on the level, other antibodies, IgG, liver tests and clinical findings.

Can the panel replace a liver biopsy?

Not always. A biopsy may be useful when results conflict, another condition is possible or the amount of inflammation needs to be assessed.